

PHARMACEUTICAL 2022



ALX ONCOLOGY HOLDINGS INC Rank 41 of 466











ALX ONCOLOGY HOLDINGS INC Rank 41 of 466 ALX ⁽⁾ NCOLOGY

The relative strengths and weaknesses of ALX ONCOLOGY HOLDINGS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALX ONCOLOGY HOLDINGS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 60% points. The greatest weakness of ALX ONCOLOGY HOLDINGS INC is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 272%, being 194% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	367,019
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,295
Liabilities, Non-Current	1,839
Other Assets	12,267
Other Compr. Net Income	0
Other Expenses	-21
Other Liabilities	0
Other Net Income	71
Other Revenues	0
Property and Equipment	897
Research and Development	60,170
Selling, General and Administrative Expense	23,385

Output Variable	Value in 1000 USD
Assets	380,183
Liabilities	17,134
Expenses	83,534
Revenues	0
Stockholders Equity	363,049
Net Income	-83,463
Comprehensive Net Income	-83,463
Economic Capital Ratio	272%

